maximum weight loss tirzepatide surmount trials for the Maintenance of Body Reduction: Rationale, Design, and Baseline Characteristics of SURMOUNT‐MAINTAIN - Horn - 2025 - Obesity Tirzepatide shows 47% greater weight

Understanding the expected appearance of compounded tirzepatide with B12 helps patients identify potential contamination or degradation issues before administration

Miller DT, Cortes-Ciriano I, Pillay N, Hirbe AC, Snuderl M, Bui MM, et al

Rare but serious side effects can include pancreatitis, gallbladder problems, or kidney issues

Some states have different rules

Allodynia and tirzepatide: is it a class effect The question of whether allodynia is specific to semaglutide or a broader GLP-1 receptor agonist class effect has significant implications for treatment decisions

Starting with GHK-Cu alone allows assessment of baseline response before adding complexity and cost